Abstract
Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade. Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures. Method: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined. Results: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures. Limitations: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult. Conclusion: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
| Original language | English (US) |
|---|---|
| Article number | e17520 |
| Journal | PLoS One |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2011 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Health outcome measures in atopic dermatitis : A systematic review of trends in disease severity and quality-of-life instruments 1985-2010. / Rehal, Balvinder; Armstrong, April.
In: PLoS One, Vol. 6, No. 4, e17520, 2011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Health outcome measures in atopic dermatitis
T2 - A systematic review of trends in disease severity and quality-of-life instruments 1985-2010
AU - Rehal, Balvinder
AU - Armstrong, April
PY - 2011
Y1 - 2011
N2 - Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade. Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures. Method: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined. Results: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures. Limitations: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult. Conclusion: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
AB - Background: A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade. Objectives: To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures. Method: All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined. Results: Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures. Limitations: The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult. Conclusion: Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=79954574126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954574126&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0017520
DO - 10.1371/journal.pone.0017520
M3 - Article
C2 - 21533286
AN - SCOPUS:79954574126
VL - 6
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 4
M1 - e17520
ER -